FDA grants approval of Mayzent to Novartis

The U.S. Food and Drug Administration approved Mayzent tablets to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. “Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We are committed to continuing to work with companies that are developing additional treatment options for patients with multiple sclerosis.” The FDA granted approval of Mayzent to Novartis.

https://thefly.com/landingPageNews.php?id=2884712